

Benedikt Fischer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3442256/publications.pdf>

Version: 2024-02-01

309
papers

10,250
citations

28272

55
h-index

60616

81
g-index

324
all docs

324
docs citations

324
times ranked

7409
citing authors

#	ARTICLE	IF	CITATIONS
1	Socio-demographic, health and drug use characteristics among people with different frequency patterns of cannabis use in Brazil. <i>Drugs: Education, Prevention and Policy</i> , 2023, 30, 425-433.	1.3	1
2	Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 3858-3868.	4.5	19
3	Proposals for Decriminalization of Illicit Drug Use: Considering a Combination of <i><i>dÃ©jÃ-vu</i></i> , Diversion and Devil-with-many-details for Health-oriented Policy Reform. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 13-15.	1.9	5
4	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. <i>International Journal of Drug Policy</i> , 2022, 99, 103381.	3.3	75
5	Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies. <i>Psychopharmacology</i> , 2022, 239, 1211-1230.	3.1	8
6	Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada. <i>International Journal of Drug Policy</i> , 2022, 100, 103480.	3.3	3
7	Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study. <i>BMC Public Health</i> , 2022, 22, 436.	2.9	6
8	Applying the socio-ecological model to understand community reintegration experiences among individuals on opioid agonist treatment (OAT) released from federal incarceration in Ontario, Canada. <i>SSM Qualitative Research in Health</i> , 2022, , 100083.	1.5	3
9	Trends in dispensing of individual prescription opioid formulations, Canada 2005â€“2020. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022, 15, 27.	2.4	0
10	Health harms of nonâ€“medical prescription opioid use: A systematic review. <i>Drug and Alcohol Review</i> , 2022, 41, 941-952.	2.1	3
11	Evaluating the populationâ€“level effects of oxycodone restrictions on prescription opioid utilization in Ontario. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	1.9	1
12	Assessing options for cannabis law reform: A Multi-Criteria Decision Analysis (MCDA) with stakeholders in New Zealand. <i>International Journal of Drug Policy</i> , 2022, 105, 103712.	3.3	21
13	Spread of Human T-Lymphotropic Virus 1 and 2 Among Relatives of People Who Use Illicit Drugs in Northern Brazil. <i>Frontiers in Microbiology</i> , 2022, 13, .	3.5	2
14	Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 726-739.	7.2	23
15	Conceptualizing and considering Cannabis-Related â€œHarm-to-Othersâ€“: The Role of Cannabis-Related Violence. <i>Substance Use and Misuse</i> , 2022, 57, 1488-1491.	1.4	4
16	Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2022, 17, .	1.6	6
17	Oral HPV among people who use crack-cocaine: prevalence, genotypes, risk factors, and key interventions in a remote Northern Brazilian region. <i>Clinical Oral Investigations</i> , 2021, 25, 759-767.	3.0	8
18	Toward a â€œPost-Legalizationâ€“Criminology for Cannabis: A Brief Review and Suggested Agenda for Research Priorities. <i>Contemporary Drug Problems</i> , 2021, 48, 58-74.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 12.	2.2	9
20	“Resurgent”, “twin” or “silent” epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 17.	2.2	31
21	New Zealand's failed cannabis legalization referendum “ implications for cannabis policy reform. The Lancet Regional Health - Western Pacific, 2021, 7, 100080.	2.9	5
22	Non-medical cannabis use among Indigenous Canadians: A systematic review of prevalence and associated factors. International Journal of Drug Policy, 2021, 90, 103081.	3.3	2
23	Factors associated with crack-cocaine early initiation: a Brazilian multicenter study. BMC Public Health, 2021, 21, 781.	2.9	4
24	Hepatitis E Virus in People Who Use Crack-Cocaine: A Cross-Sectional Study in a Remote Region of Northern Brazil. Viruses, 2021, 13, 926.	3.3	5
25	Food insecurity, chronic pain, and use of prescription opioids. SSM - Population Health, 2021, 14, 100768.	2.7	25
26	Examining a migration-based phenomenon of heroin use in an urban drug scene in Sao Paulo, Brazil. International Journal of Migration, Health and Social Care, 2021, 17, 274-285.	0.5	1
27	Correlations between Changes in Medical Opioid Dispensing and Contributions of Fentanyl to Opioid-Related Overdose Fatalities: Exploratory Analyses from Canada. International Journal of Environmental Research and Public Health, 2021, 18, 7507.	2.6	2
28	Detection and Genetic Characterization of Hepatitis B and D Viruses: A Multi-Site Cross-Sectional Study of People Who Use Illicit Drugs in the Amazon Region. Viruses, 2021, 13, 1380.	3.3	4
29	Why comparative epidemiological indicators suggest that New Zealand is unlikely to experience a severe opioid epidemic. International Journal of Drug Policy, 2021, 93, 103166.	3.3	8
30	Drug sentencing in Brazil: factors influencing sentencing outcomes in the criminal courts of Recife/PE. Journal of Criminological Research, Policy and Practice, 2021, ahead-of-print, .	0.3	1
31	Patterns, trends and determinants of medical opioid utilization in Canada 2005–2020: characterizing an era of intensive rise and fall. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 65.	2.2	6
32	Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies. European Neuropsychopharmacology, 2021, 51, 106-131.	0.7	10
33	Comparison of Crude Population-Level Indicators of Opioid Use and Related Harm in New Zealand and Ontario (Canada). Pain and Therapy, 2021, 10, 15-23.	3.2	3
34	An overview of select cannabis use and supply indicators pre- and post-legalization in Canada. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 77.	2.2	31
35	Youth Cannabis use and Legalization in Canada - Reconsidering the Fears, Myths and Facts Three Years In. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2021, 30, 191-196.	0.6	5
36	Non-medical opioid use, harms, and interventions in Canada “ a 10-year update on an unprecedented substance use-related public health crisis. Drugs: Education, Prevention and Policy, 2020, 27, 118-122.	1.3	14

#	ARTICLE	IF	CITATIONS
37	Emerging prospects for non-medical cannabis legalisation in New Zealand: An initial view and contextualization. <i>International Journal of Drug Policy</i> , 2020, 76, 102632.	3.3	8
38	Prevalence and risk factors for HIV-1 infection in people who use illicit drugs in northern Brazil. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2020, 114, 213-221.	1.8	16
39	The Lower-Risk Cannabis Use Guidelines™ (LRCUG) recommendations: How are Canadian cannabis users complying?. <i>Preventive Medicine Reports</i> , 2020, 20, 101187.	1.8	12
40	Examining correlations between opioid dispensing and opioid-related hospitalizations in Canada, 2007–2016. <i>BMC Health Services Research</i> , 2020, 20, 677.	2.2	8
41	Reflections on the Impending Lawsuits by Governments Against Pharmaceutical Opioid Producers in Canada. <i>Canadian Journal of Addiction</i> , 2020, 11, 25-27.	0.4	1
42	Some notes on the use, concept and socio-political framing of “stigma” focusing on an opioid-related public health crisis. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 54.	2.2	23
43	Recent changes in trends of opioid overdose deaths in North America. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 66.	2.2	26
44	Facing the option for the legalisation of cannabis use and supply in New Zealand: An overview of relevant evidence, concepts and considerations. <i>Drug and Alcohol Review</i> , 2020, 39, 555-567.	2.1	13
45	The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand. <i>Public Health in Practice</i> , 2020, 1, 100046.	1.5	1
46	Preventive interventions targeting cannabis use and related harms in people with psychosis: A systematic review. <i>Microbial Biotechnology</i> , 2020, 15, 1439-1453.	1.7	5
47	Prescription opioid dispensing in Canada: an update on recent developments to 2018. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 68.	2.4	23
48	Lower-Risk Cannabis Use Guidelines: Adherence in Canada and the U.S.. <i>American Journal of Preventive Medicine</i> , 2020, 59, e211-e220.	3.0	9
49	A call for greater policy and regulatory coherence for an expanding menu of legal psychoactive substances. <i>Drug and Alcohol Review</i> , 2020, 39, 737-742.	2.1	4
50	Considering the health and social welfare impacts of non-medical cannabis legalization. <i>World Psychiatry</i> , 2020, 19, 187-188.	10.4	11
51	Initial indicators of the public health impacts of non-medical cannabis legalization in Canada. <i>EClinicalMedicine</i> , 2020, 20, 100294.	7.1	18
52	“Safer opioid distribution” as an essential public health intervention for the opioid mortality crisis – Considerations, options and examples towards broad-based implementation. <i>Public Health in Practice</i> , 2020, 1, 100016.	1.5	5
53	A decade of extreme oscillations in opioid control and availability: implications for public health in a Canadian setting. <i>Journal of Public Health Policy</i> , 2020, 41, 214-220.	2.0	3
54	Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing - exploratory analyses from Canada. <i>BMC Public Health</i> , 2020, 20, 143.	2.9	35

#	ARTICLE	IF	CITATIONS
55	Applying principles of injury and infectious disease control to the opioid mortality epidemic in North America: critical intervention gaps. <i>Journal of Public Health</i> , 2020, 42, 848-852.	1.8	7
56	Hepatitis B Virus Infection among People Who Use Illicit Drugs: Prevalence, Genotypes and Risk Factors in the State of Amapá, Northern Brazil. <i>Substance Use and Misuse</i> , 2020, 55, 1633-1639.	1.4	6
57	Evaluating the intended and unintended consequences of opioid-prescribing interventions on primary care in British Columbia, Canada: protocol for a retrospective population-based cohort study. <i>BMJ Open</i> , 2020, 10, e038724.	1.9	3
58	The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis?. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 14.	2.2	36
59	A century of cannabis control in Canada. , 2020, , 89-115.		27
60	Adiponectin stimulates glucose uptake in mouse blastocysts and embryonic carcinoma cells. <i>Reproduction</i> , 2020, 159, 227-239.	2.6	4
61	New Zealand's 'Cannabis Legalisation and Regulation Bill': an evidence-based assessment and critique of essential regulatory components towards policy outcomes. <i>New Zealand Medical Journal</i> , 2020, 133, 103-111.	0.5	6
62	Tramadol dispensing patterns and trends in Canada, 2007-2016. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 396-400.	1.9	6
63	Assessing the public health impact of cannabis legalization in Canada: core outcome indicators towards an "index" for monitoring and evaluation. <i>Journal of Public Health</i> , 2019, 41, 412-421.	1.8	50
64	Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 82-87.	1.9	15
65	<i>Drug Policy and the Public Good</i>: a summary of the second edition. <i>Addiction</i> , 2019, 114, 1941-1950.	3.3	7
66	Hepatitis C virus infection status and associated factors among a multi-site sample of people who used illicit drugs in the Amazon region. <i>BMC Infectious Diseases</i> , 2019, 19, 634.	2.9	15
67	Human T-lymphotropic virus 1 and 2 among people who used illicit drugs in the state of Pará, northern Brazil. <i>Scientific Reports</i> , 2019, 9, 14750.	3.3	28
68	Guidelines for public health and safety metrics to evaluate the potential harms and benefits of cannabis regulation in Canada. <i>Drug and Alcohol Review</i> , 2019, 38, 606-621.	2.1	21
69	Potential public health impacts of medical cannabis availability on opioid-related harms? Urgent but un-answered questions from Canada. <i>International Journal of Drug Policy</i> , 2019, 73, 96-99.	3.3	3
70	The opioid death crisis in Canada: crucial lessons for public health. <i>Lancet Public Health</i> , The, 2019, 4, e81-e82.	10.0	84
71	Introducing the evidence-based population health tool of the Lower-Risk Cannabis Use Guidelines to Brazil. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 550-555.	1.7	12
72	Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. <i>PLoS Medicine</i> , 2019, 16, e1003002.	8.4	98

#	ARTICLE	IF	CITATIONS
73	Assessing service and treatment needs and barriers of youth who use illicit and non-medical prescription drugs in Northern Ontario, Canada. PLoS ONE, 2019, 14, e0225548.	2.5	20
74	Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders. Journal of the Canadian Association of Gastroenterology, 2019, 2, 37-43.	0.3	14
75	The New Zealand Government Inquiry Into Mental Health And Addiction's recommendations on substance use: some reflections from the science perspective. New Zealand Medical Journal, 2019, 132, 65-70.	0.5	0
76	Title is missing!., 2019, 16, e1003002.		0
77	Title is missing!., 2019, 16, e1003002.		0
78	Title is missing!., 2019, 16, e1003002.		0
79	Title is missing!., 2019, 16, e1003002.		0
80	Management of opioid use disorders: a national clinical practice guideline. Cmaj, 2018, 190, E247-E257.	2.0	297
81	The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. Contemporary Clinical Trials, 2018, 69, 21-27.	1.8	22
82	Routes of administration for cannabis use – basic prevalence and related health outcomes: A scoping review and synthesis. International Journal of Drug Policy, 2018, 52, 87-96.	3.3	206
83	The “fentanyl epidemic” in Canada – Some cautionary observations focusing on opioid-related mortality. Preventive Medicine, 2018, 107, 109-113.	3.4	65
84	Revisiting the “paradigm shift” in opioid use: Developments and implications 10 years later. Drug and Alcohol Review, 2018, 37, S199-S202.	2.1	32
85	Sustained Reduction in Sexual Behavior that May Pose a Risk of HIV Transmission Following Diagnosis During Early HIV Infection Among Gay Men in Vancouver, British Columbia. AIDS and Behavior, 2018, 22, 2068-2078.	2.7	6
86	Hepatitis C virus infection among illicit drug users in an archipelago of the Amazon. Archives of Virology, 2018, 163, 617-622.	2.1	16
87	Correlations between population-levels of prescription opioid dispensing and related deaths in Ontario (Canada), 2005–2016. Preventive Medicine, 2018, 116, 112-118.	3.4	13
88	Driving under the influence of prescription opioids: Self-reported prevalence and association with collision risk in a large Canadian jurisdiction. Accident Analysis and Prevention, 2018, 121, 14-19.	5.7	15
89	Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada. Drug and Alcohol Dependence, 2018, 189, 76-79.	3.2	32
90	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS ONE, 2018, 13, e0190768.	2.5	88

#	ARTICLE	IF	CITATIONS
91	Drug Policy and the Public Good. , 2018, , .		48
92	Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005â€“2016. Pain Physician, 2018, 1, 219-228.	0.4	40
93	Sourcing of opioid analgesics for nonmedical use: Are veterinarians the latest frontier?. Journal of Opioid Management, 2018, 14, 77-79.	0.5	2
94	Assessing service and treatment needs of young people who use illicit and non-medical prescription drugs living in Northern Ontario, Canada. F1000Research, 2018, 7, 1644.	1.6	0
95	Patterns of methadone maintenance treatment provision in Ontario: Policy success or pendulum excess?. Canadian Family Physician, 2018, 64, e95-e103.	0.4	8
96	Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005-2016. Pain Physician, 2018, 21, 219-228.	0.4	21
97	Risk creating and risk reducing: Community perceptions of supervised consumption facilities for illicit drug use. Health, Risk and Society, 2017, 19, 91-111.	1.7	38
98	An easy-to-build, low-budget point-of-care ultrasound simulator: from Linux to a web-based solution. The Ultrasound Journal, 2017, 9, 4.	2.0	14
99	Comparing Medical and Recreational Cannabis Users on Socio-Demographic, Substance and Medication Use, and Health and Disability Characteristics. European Addiction Research, 2017, 23, 129-135.	2.4	16
100	Estimating the harms and costs of cannabis-attributable collisions in the Canadian provinces. Drug and Alcohol Dependence, 2017, 173, 185-190.	3.2	42
101	Substance Use, Health, and Functioning Characteristics of Medical Marijuana Program Participants Compared to the General Adult Population in Ontario (Canada). Journal of Psychoactive Drugs, 2017, 49, 31-38.	1.7	10
102	Reflections on Pollini et al. (2017)â€”Implications for Interventions for Driving While Using Psychotropic Medications With Impairment Risk. Journal of Studies on Alcohol and Drugs, 2017, 78, 814-816.	1.0	6
103	Health outcomes associated with crack-cocaine use: Systematic review and meta-analyses. Drug and Alcohol Dependence, 2017, 180, 401-416.	3.2	114
104	Commentary on Fazel <i>et al</i>. (2017): High levels of substance use disorders among correctional inmatesâ€”some implications for interventions of the review data from Fazel <i>et al</i>.. Addiction, 2017, 112, 1740-1741.	3.3	1
105	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017, 107, 1277-1277.	2.7	25
106	Cannabis use, legalization and youth health. Cmaj, 2017, 189, E971-E972.	2.0	8
107	â€”Delistingâ€™ OxyContinÂ® to reduce prescription opioidâ€”related harms in Ontario (Canada)â€”gauging effects 5Â”years later. Pharmacoepidemiology and Drug Safety, 2017, 26, 1040-1043.	1.9	14
108	Fischer et al. Respond. American Journal of Public Health, 2017, 107, e26-e27.	2.7	1

#	ARTICLE	IF	CITATIONS
109	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017, 107, e1-e12.	2.7	295
110	The impact of medical and non-medical prescription opioid use on motor vehicle collision risk. Transportation Research Part F: Traffic Psychology and Behaviour, 2017, 47, 155-162.	3.7	9
111	Characterization of hepatitis B virus infection in illicit drug users in the Marajó Archipelago, northern Brazil. Archives of Virology, 2017, 162, 227-233.	2.1	19
112	Legalisation of non-medical cannabis in Canada: will supply regulations effectively serve public health?. Lancet Public Health, The, 2017, 2, e536-e537.	10.0	14
113	The Devil Is in the Details! On Regulating Cannabis Use in Canada Based on Public Health Criteria Comment on "Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts". International Journal of Health Policy and Management, 2017, 6, 173-176.	0.9	7
114	Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995. Clinical Drug Investigation, 2016, 36, 519-530.	2.2	37
115	The Cannabis Policy Framework by the Centre for Addiction and Mental Health: A proposal for a public health approach to cannabis policy in Canada. International Journal of Drug Policy, 2016, 34, 1-4.	3.3	28
116	Depression – A major but neglected consequence contributing to the health toll from prescription opioids?. Psychiatry Research, 2016, 243, 331-334.	3.3	19
117	On the relationship between epidemiology and policy. Addiction, 2016, 111, 1687-1688.	3.3	1
118	Policy Measures for Prescription Opioids and Harms: Enough to Protect Public Health? A Comment on Yanovitzky (2016) and Piper et al. (2016). Journal of Studies on Alcohol and Drugs, 2016, 77, 566-567.	1.0	2
119	Effective Canadian policy to reduce harms from prescription opioids: learning from past failures. Cmaj, 2016, 188, 1240-1244.	2.0	80
120	The burden of disease attributable to cannabis use in Canada in 2012. Addiction, 2016, 111, 653-662.	3.3	83
121	Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany. International Journal of Drug Policy, 2016, 29, 57-65.	3.3	14
122	Policy implications of marked reversals of population life expectancy caused by substance use. BMC Medicine, 2016, 14, 42.	5.5	22
123	Treatment of prescription opioid disorders in Canada: looking at the “other epidemic?”. Substance Abuse Treatment, Prevention, and Policy, 2016, 11, 12.	2.2	28
124	Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence. Journal of Addiction Medicine, 2016, 10, 274-279.	2.6	32
125	Realistically furthering the goals of public health by cannabis legalization with strict regulation: Response to Kalant. International Journal of Drug Policy, 2016, 34, 11-16.	3.3	19
126	Crude estimates of cannabis-attributable mortality and morbidity in Canada – implications for public health focused intervention priorities. Journal of Public Health, 2016, 38, 183-188.	1.8	54

#	ARTICLE	IF	CITATIONS
127	The effectiveness of compulsory drug treatment: A systematic review. <i>International Journal of Drug Policy</i> , 2016, 28, 1-9.	3.3	159
128	Characteristics of clients using a community-based drug treatment service (â€ˆCAPS-ADâ€™™) in Brazil: An exploratory study. <i>International Journal of Drug Policy</i> , 2016, 31, 99-103.	3.3	13
129	Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. <i>Drug and Alcohol Dependence</i> , 2016, 161, 298-306.	3.2	70
130	Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000. <i>International Journal of Drug Policy</i> , 2016, 27, 23-35.	3.3	32
131	Public Opinion towards Cannabis Control in Ontario: Strong but Diversified Support for Reforming Control of Both Use and Supply. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2016, 58, 443-459.	0.5	10
132	Prescription opioid prescribing, use/misuse, harms and treatment among Aboriginal people in Canada: a narrative review of available data and indicators. <i>Rural and Remote Health</i> , 2016, 16, 3974.	0.5	12
133	Prescription opioids, abuse and public health in Canada: is fentanyl the new centre of the opioid crisis?. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1334-1336.	1.9	21
134	Cannabis vaping and public healthâ€™some comments on relevance and implications. <i>Addiction</i> , 2015, 110, 1705-1706.	3.3	11
135	Factors associated with recidivism among adolescents girls in conflict with the law in an institution in BrasÃlia, Federal District, Brazil. <i>Cadernos De Saude Publica</i> , 2015, 31, 2569-2576.	1.0	0
136	Substance Use and Related Harms among Aboriginal People in Canada: A Comprehensive Review. <i>Journal of Health Care for the Poor and Underserved</i> , 2015, 26, 1110-1131.	0.8	33
137	Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: A comprehensive narrative overview of English-language studies. <i>International Journal of Drug Policy</i> , 2015, 26, 352-363.	3.3	64
138	Cannabis legalization with strict regulation, the overall superior policy option for public health. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 541-544.	4.7	51
139	Medical marijuana programs â€™ Why might they matter for public health and why should we better understand their impacts?. <i>Preventive Medicine Reports</i> , 2015, 2, 53-56.	1.8	20
140	Considerations towards a population health approach to reduce prescription opioid-related harms (with a primary focus on Canada). <i>Drugs: Education, Prevention and Policy</i> , 2015, 22, 60-65.	1.3	2
141	Addressing the stimulant treatment gap: A call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use. <i>International Journal of Drug Policy</i> , 2015, 26, 1177-1182.	3.3	35
142	Medical Marijuana programs: Implications for cannabis control policy â€™ Observations from Canada. <i>International Journal of Drug Policy</i> , 2015, 26, 15-19.	3.3	73
143	Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010. <i>Pain Physician</i> , 2015, 18;4, E605-E614.	0.4	22
144	Recent Developments in Prescription Opioidrelated Dispensing and Harm Indicators in Ontario, Canada. <i>Pain Physician</i> , 2015, 18;4, E662-E662.	0.4	1

#	ARTICLE	IF	CITATIONS
145	Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010. <i>Pain Physician</i> , 2015, 18, E605-14.	0.4	36
146	Recent Developments in Prescription Opioid-related Dispensing and Harm Indicators in Ontario, Canada. <i>Pain Physician</i> , 2015, 18, E659-62.	0.4	12
147	Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: An update 5 years later. <i>Canadian Journal of Public Health</i> , 2014, 105, e146-e149.	2.3	52
148	Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in <sc>O</sc>ntario, <sc>C</sc>anada, 2005â€“2011. <i>Drug and Alcohol Review</i> , 2014, 33, 19-26.	2.1	78
149	High levels of opioid analgesic coâ€“prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a populationâ€“level retrospective cohort study. <i>American Journal on Addictions</i> , 2014, 23, 257-264.	1.4	24
150	Assessing the Impact of Methadone Maintenance Treatment (MMT) on Post-release Recidivism among Male Federal Correctional Inmates in Canada. <i>Criminal Justice and Behavior</i> , 2014, 41, 380-394.	1.8	20
151	Harms of prescription opioid use in the United States. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2014, 9, 43.	2.2	35
152	Impact of Methadone Maintenance Treatment on Women Offenders' Post-Release Recidivism. <i>European Addiction Research</i> , 2014, 20, 192-199.	2.4	31
153	Reflections Regarding Future Cannabis Use Among Highâ€“Frequency Users in a <sc>C</sc>anadian <sc>U</sc>niversity Student Population. <i>Journal of Research on Adolescence</i> , 2014, 24, 598-607.	3.7	2
154	Considering prescription opioidâ€“related harms in the population: Response to commentaries. <i>Addiction</i> , 2014, 109, 186-188.	3.3	1
155	Increasing public support for supervised injection facilities in Ontario, Canada. <i>Addiction</i> , 2014, 109, 946-953.	3.3	34
156	Comparing key characteristics of young adult crack users in and out-of-treatment in Rio de Janeiro, Brazil. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2014, 9, 2.	2.2	18
157	Exploring sex differences in drug use, health and service use characteristics among young urban crack users in Brazil. <i>International Journal for Equity in Health</i> , 2014, 13, 70.	3.5	33
158	Trends and changes in prescription opioid analgesic dispensing in Canada 2005â€“2012: an update with a focus on recent interventions. <i>BMC Health Services Research</i> , 2014, 14, 90.	2.2	77
159	Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: Systematic review and meta-analyses. <i>Addictive Behaviors</i> , 2014, 39, 520-531.	3.0	85
160	Nonâ€“medical use of prescription opioids and prescription opioidâ€“related harms: why so markedly higher in <sc>N</sc>orth <sc>A</sc>merica compared to the rest of the world?. <i>Addiction</i> , 2014, 109, 177-181.	3.3	129
161	A Narrative Review of Recent Developments in Knowledge Translation and Implications for Mental Health Care Providers. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 160-169.	1.9	25
162	Factors Associated with High-Frequency Cannabis Use and Driving among a Multi-site Sample of University Students in Ontario. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2014, 56, 185-200.	0.5	15

#	ARTICLE	IF	CITATIONS
163	Structural barriers in the context of opiate substitution treatment in Germany - a survey among physicians in primary care. Substance Abuse Treatment, Prevention, and Policy, 2013, 8, 26.	2.2	20
164	Reductions in non-medical prescription opioid use among adults in Ontario, Canada: are recent policy interventions working?. Substance Abuse Treatment, Prevention, and Policy, 2013, 8, 7.	2.2	10
165	Assessing the prevalence of non-medical prescription opioid use in the Canadian general adult population: evidence of large variation depending on survey questions used. BMC Psychiatry, 2013, 13, 6.	2.6	14
166	Patterns, determinants and barriers of health and social service utilization among young urban crack users in Brazil. BMC Health Services Research, 2013, 13, 536.	2.2	32
167	Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada. Drug and Alcohol Review, 2013, 32, 276-287.	2.1	44
168	Feasibility and impact of brief interventions for frequent cannabis users in Canada. Journal of Substance Abuse Treatment, 2013, 44, 132-138.	2.8	38
169	Crack across the Americas – A massive problem in continued search of viable answers: Exemplary views from the North (Canada) and the South (Brazil). International Journal of Drug Policy, 2013, 24, 631-633.	3.3	34
170	Key drug use, health and socio-economic characteristics of young crack users in two Brazilian cities. International Journal of Drug Policy, 2013, 24, 432-438.	3.3	69
171	Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada. CMAJ Open, 2013, 1, E68-E76.	2.4	11
172	“Hard to crack”: Experiences of community integration among first- and second-generation Asian MSM in Canada.. Cultural Diversity and Ethnic Minority Psychology, 2013, 19, 248-256.	2.0	63
173	Crack Pipe Sharing in Context: How Sociostructural Factors Shape Risk Practices among Noninjection Drug Users. Contemporary Drug Problems, 2013, 40, 481-503.	1.6	13
174	High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005 – 2009. Pharmacoepidemiology and Drug Safety, 2013, 22, 438-442.	1.9	77
175	High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study. American Journal on Addictions, 2013, 23, n/a-n/a.	1.4	1
176	Use and Nonmedical Use of Prescription Opioid Analgesics in the General Population of Canada and Correlations with Dispensing Levels in 2009. Pain Research and Management, 2013, 18, 69-74.	1.8	27
177	Prevalence of pain among nonmedical prescription opioid users in substance use treatment populations: systematic review and meta-analyses. Pain Physician, 2013, 16, E671-84.	0.4	17
178	Characteristics and predictors of health problems from use among high-frequency cannabis users in a Canadian university student population. Drugs: Education, Prevention and Policy, 2012, 19, 49-58.	1.3	6
179	Brief Intervention Experiences of Young High-Frequency Cannabis Users in a Canadian Setting. Contemporary Drug Problems, 2012, 39, 49-72.	1.6	2
180	Drug policy and the public good: evidence for effective interventions. Lancet, The, 2012, 379, 71-83.	13.7	205

#	ARTICLE	IF	CITATIONS
181	The Prevalence of Mental Health and Pain Symptoms in General Population Samples Reporting Nonmedical Use of Prescription Opioids: A Systematic Review and Meta-Analysis. <i>Journal of Pain</i> , 2012, 13, 1029-1044.	1.4	66
182	Correlations between population levels of prescription opioid use and prescription-opioid-related substance use treatment admissions in the USA and Canada since 2001. <i>Public Health</i> , 2012, 126, 749-751.	2.9	23
183	“Opioid Drought”™, Canadian-style? Potential implications of the “natural experiment”™ of delisting Oxycontin in Canada. <i>International Journal of Drug Policy</i> , 2012, 23, 495-497.	3.3	18
184	Police Perceptions of Supervised Consumption Sites (SCSs): A Qualitative Study. <i>Substance Use and Misuse</i> , 2012, 47, 364-374.	1.4	36
185	Prevalence and trends of non-medical opioid and other drug use histories among federal correctional inmates in methadone maintenance treatment in Canada. <i>Drug and Alcohol Dependence</i> , 2012, 124, 172-176.	3.2	14
186	12-month follow-up of an exploratory “brief intervention”™ for high-frequency cannabis users among Canadian university students. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2012, 7, 15.	2.2	20
187	Increases in the availability of prescribed opioids in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2012, 126, 7-12.	3.2	23
188	Estimating the economic value of British Columbia's domestic cannabis market: Implications for provincial cannabis policy. <i>International Journal of Drug Policy</i> , 2012, 23, 436-441.	3.3	20
189	Use of other opioids during methadone therapy: a population-based study. <i>Addiction</i> , 2012, 107, 776-780.	3.3	23
190	Prescription Opioid Related Misuse, Harms, Diversion and Interventions in Canada: A Review. <i>Pain Physician</i> , 2012, 3S;15, ES191-ES203.	0.4	142
191	Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. <i>Pain Physician</i> , 2012, 15, ES191-203.	0.4	108
192	Lower Risk Cannabis Use Guidelines for Canada (LRCUG): A Narrative Review of Evidence and Recommendations. <i>Canadian Journal of Public Health</i> , 2011, 102, 324-327.	2.3	72
193	Non-medical Use of Prescription Opioids Among Ontario Adults: Data From the 2008/2009 CAMH Monitor. <i>Canadian Journal of Public Health</i> , 2011, 102, 330-335.	2.3	22
194	Nonmedical Prescription Opioid Use and Mental Health and Pain Comorbidities: A Narrative Review. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 495-502.	1.9	70
195	MAKING SPACE FOR CANNABIS POLICY EXPERIMENTS. <i>Addiction</i> , 2011, 106, 1192-1193.	3.3	2
196	NUTT ET AL.'S HARM SCALES FOR DRUGS-ROOM FOR IMPROVEMENT BUT BETTER POLICY BASED ON SCIENCE WITH LIMITATIONS THAN NO SCIENCE AT ALL. <i>Addiction</i> , 2011, 106, 1891-1892.	3.3	26
197	Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. <i>Journal of Viral Hepatitis</i> , 2011, 18, 32-41.	2.0	48
198	Uptake, benefits of and barriers to safer crack use kit (SCUK) distribution programmes in Victoria, Canada—A qualitative exploration. <i>International Journal of Drug Policy</i> , 2011, 22, 292-300.	3.3	40

#	ARTICLE	IF	CITATIONS
199	Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005–2010. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1269-1277.	1.9	72
200	Prevalence and Characteristics of Substance Use Among Chinese and South Asians in Canada. <i>Journal of Ethnicity in Substance Abuse</i> , 2011, 10, 39-47.	0.9	12
201	“What a pity!” Exploring the use of “pitolho” as harm reduction among crack users in Salvador, Brazil. <i>Drugs: Education, Prevention and Policy</i> , 2011, 18, 382-386.	1.3	13
202	Prescription opioid abuse: what is the real problem and how do we fix it?. <i>Canadian Family Physician</i> , 2011, 57, 1241-2, e403-5.	0.4	8
203	Research, Policy Development, and Progress: Antisocial Behaviour and the Automobile. <i>Canadian Public Policy/ Analyse De Politiques</i> , 2010, 36, S81-S93.	1.6	10
204	Assessing the Prevalence of Nonmedical Prescription Opioid Use in the General Canadian Population: Methodological Issues and Questions. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 606-609.	1.9	20
205	A heroin prescription trial: Case studies from Montreal and Vancouver on crime and disorder in the surrounding neighbourhoods. <i>International Journal of Drug Policy</i> , 2010, 21, 28-35.	3.3	13
206	Typologies of cannabis users and associated characteristics relevant for public health: a latent class analysis of data from a nationally representative Canadian adult survey. <i>International Journal of Methods in Psychiatric Research</i> , 2010, 19, 110-124.	2.1	32
207	Commentary on Ware and St Arnaud–Trempe (2010): Nabilone abuse in Canada? Nature provides an effective prevention program. <i>Addiction</i> , 2010, 105, 504-505.	3.3	1
208	The Global Diversion of Pharmaceutical Drugs–Non-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. <i>Addiction</i> , 2010, 105, 2062-2070.	3.3	75
209	Social, health and drug use characteristics of primary crack users in three mid-sized communities in British Columbia, Canada. <i>Drugs: Education, Prevention and Policy</i> , 2010, 17, 333-353.	1.3	21
210	Factors Associated with Treatment Compliance and its Effects on Retention among Participants in a Court-Mandated Treatment Program. <i>Contemporary Drug Problems</i> , 2010, 37, 289-313.	1.6	10
211	Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004–2009. <i>Drug and Alcohol Dependence</i> , 2010, 109, 257-260.	3.2	40
212	Cannabis Use in Canada: The Need for a “Public Health” Approach. <i>Canadian Journal of Public Health</i> , 2009, 100, 101-103.	2.3	48
213	How Many People in Canada Use Prescription Opioids Nonmedically in General and Street Drug Using Populations?. <i>Canadian Journal of Public Health</i> , 2009, 100, 104-108.	2.3	22
214	Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. <i>Cmaj</i> , 2009, 181, 585-589.	2.0	116
215	Deaths related to the use of prescription opioids. <i>Cmaj</i> , 2009, 181, 881-882.	2.0	32
216	Proportional Hazards Frailty Models for Recurrent Methadone Maintenance Treatment. <i>American Journal of Epidemiology</i> , 2009, 170, 783-792.	3.4	85

#	ARTICLE	IF	CITATIONS
217	Fentanyl use among street drug users in Toronto, Canada: Behavioural dynamics and public health implications. <i>International Journal of Drug Policy</i> , 2009, 20, 90-92.	3.3	43
218	Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. <i>Journal of Viral Hepatitis</i> , 2009, 16, 352-358.	2.0	162
219	Thinking the unthinkable: Could the increasing misuse of prescription opioids among street drug users offer benefits for public health?. <i>Public Health</i> , 2009, 123, 145-146.	2.9	10
220	Methamphetamine Injection Independently Predicts Hepatitis C Infection Among Street-Involved Youth in a Canadian Setting. <i>Journal of Adolescent Health</i> , 2009, 44, 302-304.	2.5	30
221	Profiling poly-substance use typologies in a multi-site cohort of illicit opioid and other drug users in Canada—a latent class analysis. <i>Addiction Research and Theory</i> , 2009, 17, 168-185.	1.9	32
222	Prescription drug abuse and methods of diversion: The potential role of a pharmacy network. <i>Journal of Substance Use</i> , 2009, 14, 75-83.	0.7	14
223	Exploring Drug Sourcing among Regular Prescription Opioid Users in Canada: Data from Toronto and Victoria. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2009, 51, 55-72.	0.5	4
224	A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: behaviours, preferences and drug availability. <i>Harm Reduction Journal</i> , 2008, 5, 30.	3.2	46
225	Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. <i>Drug and Alcohol Review</i> , 2008, 27, 625-632.	2.1	73
226	Predictors of methadone maintenance treatment utilization in a multisite cohort of illicit opioid users (OPICAN). <i>Journal of Substance Abuse Treatment</i> , 2008, 34, 340-346.	2.8	15
227	Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. <i>Drug and Alcohol Dependence</i> , 2008, 93, 141-147.	3.2	180
228	Nonmedical Use of Prescription Opioids: Furthering a Meaningful Research Agenda. <i>Journal of Pain</i> , 2008, 9, 490-493.	1.4	14
229	Beyond the barriers: marking the place for marijuana use at a Canadian high school. <i>Journal of Youth Studies</i> , 2008, 11, 47-64.	2.3	10
230	Should heroin be prescribed to heroin misusers? Yes. <i>BMJ: British Medical Journal</i> , 2008, 336, 70-70.	2.3	10
231	Hepatitis C virus transmission among oral crack users: viral detection on crack paraphernalia. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 29-32.	1.6	74
232	Non-medical Use of Prescription Opioids and Public Health in Canada. <i>Canadian Journal of Public Health</i> , 2008, 99, 182-184.	2.3	39
233	Characterizing the “Awakening Elephant” of Prescription Opioid Misuse in North America: Epidemiology, Harms, Interventions. <i>Contemporary Drug Problems</i> , 2008, 35, 397-426.	1.6	22
234	Reduction in Injection-Related HIV Risk After 6 Months in a Low-Threshold Methadone Treatment Program. <i>AIDS Education and Prevention</i> , 2007, 19, 124-136.	1.1	49

#	ARTICLE	IF	CITATIONS
235	The Costs of Alcohol, Illegal Drugs, and Tobacco in Canada, 2002. Journal of Studies on Alcohol and Drugs, 2007, 68, 886-895.	1.0	126
236	Illicit Opioid Use and its Key Characteristics: A Select Overview and Evidence from a Canadian Multisite Cohort of Illicit Opioid Users. Canadian Journal of Psychiatry, 2007, 52, 335-336.	1.9	0
237	Local Drug-Related Crime Dynamics in a Canadian Multi-Site Sample of Untreated Opioid Users. Canadian Journal of Criminology and Criminal Justice, 2007, 49, 341-373.	0.5	5
238	Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. Drug and Alcohol Dependence, 2007, 88, 1-8.	3.2	129
239	Injection Drug Use, Multiple Hepatitis Virus Infections, and Migration: A German Study. Substance Use and Misuse, 2007, 42, 1353-1365.	1.4	6
240	Prevalence and Associated Factors of Hepatitis C Infection (HCV) in a Multi-site Canadian Population of Illicit Opioid and Other Drug Users (OPICAN). Canadian Journal of Public Health, 2007, 98, 130-133.	2.3	14
241	Multiple viral hepatitis in injection drug users and associated risk factors. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 80-85.	2.8	47
242	Illicit opioid use in the 21st century: witnessing a paradigm shift?. Addiction, 2007, 102, 499-501.	3.3	58
243	Crack use in North American cities: the neglected "epidemic". Addiction, 2007, 102, 1340-1341.	3.3	39
244	[Commentary] UNDERSTANDING THE PARAMETERS OF NON-MEDICAL USE OF PRESCRIPTION DRUGS: MOVING BEYOND MERE NUMBERS. Addiction, 2007, 102, 1931-1932.	3.3	10
245	Public opinion towards supervised injection facilities and heroin-assisted treatment in Ontario, Canada. International Journal of Drug Policy, 2007, 18, 54-61.	3.3	52
246	Heroin-assisted Treatment (HAT) a Decade Later: A Brief Update on Science and Politics. Journal of Urban Health, 2007, 84, 552-562.	3.6	107
247	Drug treatment courts in Canada: an evidence-based review. Hiv/aids Policy * Law Review / Canadian Hiv/aids Legal Network, 2007, 12, 12-7.	0.0	13
248	Determinants of Property Crime Among Illicit Opiate Users Outside of Treatment Across Canada. Deviant Behavior, 2006, 27, 351-376.	1.7	43
249	Change in health-related quality of life of opiate users in low-threshold methadone programs. Journal of Substance Use, 2006, 11, 137-149.	0.7	21
250	An overview of illegal opioid use and health services utilization in Canada. Public Health, 2006, 120, 320-328.	2.9	46
251	Illicit Opioid Use and Treatment for Opioid Dependence: Challenges for Canada and beyond. Canadian Journal of Psychiatry, 2006, 51, 621-623.	1.9	9
252	Health and Social Services Accessed by a Cohort of Canadian Illicit Opioid Users Outside of Treatment. Canadian Journal of Public Health, 2006, 97, 166-170.	2.3	11

#	ARTICLE	IF	CITATIONS
253	Hepatitis C, Illicit Drug Use and Public Health. Canadian Journal of Public Health, 2006, 97, 485-488.	2.3	9
254	Drug-related Overdose Deaths in British Columbia and Ontario, 1992â€“2004. Canadian Journal of Public Health, 2006, 97, 384-387.	2.3	11
255	Illicit Opioid Use and its Key Characteristics: A Select Overview and Evidence from a Canadian Multisite Cohort of Illicit Opioid Users (OPICAN). Canadian Journal of Psychiatry, 2006, 51, 624-634.	1.9	50
256	Crack across Canada: comparing crack users and crack non-users in a Canadian multi-city cohort of illicit opioid users. Addiction, 2006, 101, 1760-1770.	3.3	81
257	Toking and driving: Characteristics of Canadian university students who drive after cannabis useâ€”an exploratory pilot study. Drugs: Education, Prevention and Policy, 2006, 13, 179-187.	1.3	37
258	Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions. European Journal of Gastroenterology and Hepatology, 2006, 18, 1039-1042.	1.6	9
259	Changes in illicit opioid use across Canada. Cmaj, 2006, 175, 1385-1385.	2.0	125
260	Comparing Injecting and Non-Injecting Illicit Opioid Users in a Multisite Canadian Sample (OPICAN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.4	39
261	Determinants of Health-Related Quality of Life of Opiate Users at Entry to Low-Threshold Methadone Programs. European Addiction Research, 2006, 12, 74-82.	2.4	55
262	Patterns of opioid and cocaine co-use: A descriptive study in a Canadian sample of untreated opioid-dependent individuals.. Experimental and Clinical Psychopharmacology, 2005, 13, 303-310.	1.8	28
263	Illicit Opioid Use in Canada: Comparing Social, Health, and Drug Use Characteristics of Untreated Users in Five Cities (OPICAN Study). Journal of Urban Health, 2005, 82, 250-266.	3.6	149
264	Prescription Drug Abuse in Canada and the Diversion of Prescription Drugs into the Illicit Drug Market. Canadian Journal of Public Health, 2005, 96, 459-461.	2.3	43
265	Crack Use As a Public Health Problem in Canada. Canadian Journal of Public Health, 2005, 96, 185-188.	2.3	57
266	Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison Population. American Journal of Public Health, 2005, 95, 1737-1739.	2.7	41
267	Dealing with prostitution in Canada. Cmaj, 2005, 172, 13-14.	2.0	1
268	Policy Changes and the Methadone Maintenance Treatment System for Opioid Dependence in Ontario, 1996 to 2001. Journal of Addictive Diseases, 2005, 24, 39-51.	1.3	23
269	Eyes Wide Shut? â€” A Conceptual and Empirical Critique of Methadone Maintenance Treatment. European Addiction Research, 2005, 11, 1-14.	2.4	68
270	Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes. International Journal of Prisoner Health, 2005, 1, 13-18.	0.9	5

#	ARTICLE	IF	CITATIONS
271	Prostitutes are people too. <i>Lancet, The</i> , 2005, 366, 1264-1265.	13.7	21
272	Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. <i>Addictive Behaviors</i> , 2005, 30, 1025-1028.	3.0	50
273	Self-perceived Health Among Canadian Opiate Users. <i>Canadian Journal of Public Health</i> , 2004, 95, 99-103.	2.3	77
274	Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. <i>Cmaj</i> , 2004, 171, 235-239.	2.0	86
275	How Drug using men who have sex with men account for substance use during Sexual Behaviours: Questioning assumptions of Hiv Prevention and Research. <i>Addiction Research and Theory</i> , 2004, 12, 213-229.	1.9	29
276	Drug use, risk and urban order: examining supervised injection sites (SISs) as "governmentality". <i>International Journal of Drug Policy</i> , 2004, 15, 357-365.	3.3	88
277	Injection Drug Use and the Hepatitis C Virus: Considerations for a Targeted Treatment Approach--The Case Study of Canada. <i>Journal of Urban Health</i> , 2004, 81, 428-447.	3.6	65
278	Cannabis Law Reform in Canada: Is the "Saga of Promise, Hesitation and Retreat" Coming to an End?1. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2003, 45, 265-298.	0.5	38
279	Editorial. <i>European Addiction Research</i> , 2002, 8, 52-53.	2.4	7
280	Heroin-assisted treatment as a response to the public health problem of opiate dependence. <i>European Journal of Public Health</i> , 2002, 12, 228-234.	0.3	82
281	CANADIAN ILLICIT OPIATE USERS' VIEWS ON METHADONE AND OTHER OPIATE PRESCRIPTION TREATMENT: AN EXPLORATORY QUALITATIVE STUDY. <i>Substance Use and Misuse</i> , 2002, 37, 495-522.	1.4	86
282	Compulsory Drug Treatment in Canada: Historical Origins and Recent Developments. <i>European Addiction Research</i> , 2002, 8, 61-68.	2.4	17
283	SUBSTITUTION THERAPY FOR HEROIN ADDICTION. <i>Substance Use and Misuse</i> , 2002, 37, 1149-1178.	1.4	34
284	Heroin prescription for opioid addicts. <i>Lancet, The</i> , 2002, 359, 890.	13.7	0
285	Safer Injection Facilities (SIFs) for Injection Drug Users (IDUs) in Canada. <i>Canadian Journal of Public Health</i> , 2002, 93, 336-338.	2.3	17
286	Methadone treatment in Ontario after the 1996 regulation reforms. Results of a physician survey. <i>Annales De Médecine Interne</i> , 2002, 153, 2S11-21.	0.2	4
287	Some Reflections on the Relationship of Risk, Harm and Responsibility in Recent Tobacco Lawsuits, and Implications for Public Health. <i>Canadian Journal of Public Health</i> , 2001, 92, 7-8.	2.3	1
288	Illicit opiates and crime: Results of an untreated user cohort study in Toronto. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2001, 43, 197-217.	0.3	15

#	ARTICLE	IF	CITATIONS
289	Consideration of a North American heroin-assisted clinical trial for the treatment of opiate-dependent individuals. <i>International Journal of Drug Policy</i> , 2000, 11, 357-370.	3.3	10
290	Social costs of untreated opioid dependence. <i>Journal of Urban Health</i> , 2000, 77, 688-722.	3.6	91
291	Prescriptions, Power and Politics: The Turbulent History of Methadone Maintenance in Canada. <i>Journal of Public Health Policy</i> , 2000, 21, 187.	2.0	55
292	Injection drug use and preventive measures: a comparison of Canadian and western European jurisdictions over time. <i>Cmaj</i> , 2000, 162, 1709-13.	2.0	19
293	Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. <i>Journal of Public Health Policy</i> , 2000, 21, 187-210.	2.0	29
294	Comparing Opiate Users in Methadone Treatment with Untreated Opiate Users: Results of a Follow-up Study with a Toronto Opiate User Cohort. <i>Canadian Journal of Public Health</i> , 1999, 90, 299-303.	2.3	28
295	Prohibition, public health and a window of opportunity: An analysis of Canadian drug policy, 1985â€“1997. <i>Policy Studies</i> , 1999, 20, 197-210.	1.6	15
296	Illicit Opiates in Toronto: A Profile of Current Users. <i>Addiction Research</i> , 1999, 7, 377-415.	0.6	57
297	Effects of Environmental Pollutants on Reproduction, Euroconference Halle, 11â€“13 April 1997. <i>Reproduction in Domestic Animals</i> , 1998, 33, 1-3.	1.4	0
298	Exclusion, â€˜riskâ€™, and social controlâ€™ reflections on community policing and public health. <i>Geoforum</i> , 1998, 29, 187-197.	2.5	64
299	Marijuana, juveniles, and the police: What high-school students believe about detection and enforcement. <i>Canadian Journal of Criminology and Criminal Justice</i> , 1998, 40, 401-420.	0.3	8
300	Charting WHOâ€™s goals for licit and illicit drugs for the year 2000 are we 'on track'?. <i>Public Health</i> , 1997, 111, 271-275.	2.9	29
301	The Case for a Heroin Substitution Treatment Trial in Canada. <i>Canadian Journal of Public Health</i> , 1997, 88, 367-370.	2.3	43
302	Drugs, Communities, and "Harm Reduction" in Germany: The New Relevance of "Public Health" Principles in Local Responses. <i>Journal of Public Health Policy</i> , 1995, 16, 389.	2.0	16
303	Drugs, communities, and "harm reduction" in Germany: the new relevance of "public health" principles in local responses. <i>Journal of Public Health Policy</i> , 1995, 16, 389-411.	2.0	8
304	Ultrastructural and Autoradiographic study of Preimplantation rabbit embryos grown in conventional or uterine flushing-supplemented culture media. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1992, 28, 337-347.	1.5	3
305	Embryonic development and incidence of aneuploidy in two rabbit strains of different fecundity. <i>Reproduction</i> , 1991, 92, 41-46.	2.6	12
306	Development of preimplantation rabbit embryos in uterine flushing-supplemented culture media. <i>Molecular Reproduction and Development</i> , 1990, 27, 216-223.	2.0	19

#	ARTICLE	IF	CITATIONS
307	Effects of asynchrony on rabbit blastocyst development. <i>Reproduction</i> , 1989, 86, 479-491.	2.6	16
308	Potential risk of light and room temperature exposure to preimplantation embryos. <i>Fertility and Sterility</i> , 1988, 50, 938-944.	1.0	47
309	Assessing service and treatment needs of young people who use illicit and non-medical prescription drugs living in Northern Ontario, Canada. <i>F1000Research</i> , 0, 7, 1644.	1.6	0